# US 2022/0064194 A1 · Organophosphorus-substituted compounds as c-met inhibitors and therapeutic uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0064194 A1
- Document ID: US20220064194A1
- Status: Published application
- Kind: A1
- Application number: 17/312,669
- Filed: 2019-12-14
- Published: 2022-03-03
- Earliest claimed: 2018-12-14
- Assignees: Beta Pharma, Inc.
- Applicants: Beta Pharma, Inc.
- Inventors: Don ZHANG; Jirong PENG; Michael Nicholas GRECO; Michael John COSTANZO; Michael Alan GREEN
- Web page: https://patentgrep.com/patent/US20220064194A1

## CPC

- C07F 9/6561: containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61P 35/00: Antineoplastic agents
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides [1,2,4]triazolo[4,3-b][1,2,4]triazine, [1,2,4] triazolo[4,3-b]pyridazine, and [1,2,3]triazolo[4,5-b]pyrazine derivatives, and pharmaceutically acceptable salts, solvates or prodrugs thereof, as tyrosine kinase c-MET inhibitors, which are useful as novel anticancer and/or anti-inflammatory agents.

## Claims

### Claim 1

A compound of formula (I):
or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein:
A is absent (i.e., a direct bond), arylene or heteroarylene, each optionally substituted by one to four substituents independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, C1-C6 acyl, cyano, nitro, and NRcRd;
L is absent (i.e., a direct bond), O, S, NR1, C(O), or C(RL)2, wherein RL at each occurrence is independently hydrogen, halogen, or C1-C4 alkyl;
Q is absent (i.e., a direct bond) or C(RQ)2, wherein RQ at each occurrence is independently hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, or C1-C4 haloalkoxy;
X and Y are each C or N;
Z is CRZ or N, wherein RZ is hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, or C1-C4 haloalkoxy;
when X is C and Y is N, then W is O, NR1, S, or CR5R6;
when X is N, then W is CR5R6,
R1 is H or C1-C6 alkyl;
R2 and R3 are each independently alkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, —OR4, —NR7R8, or —OCH2(C═O)OR9, wherein said alkyl, aryl, cycloalkyl, heteroaryl, or heterocyclyl is each optionally substituted by one to five substituents independently selected from the group consisting of C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C6-C10 aryl, 5- to 10-membered heteroaryl, C3-C6 cycloalkyl, 3- to 10-membered heterocyclyl, halogen, cyano, nitro, —OR9, —SR9, —C(O)OR9, —C(O)R10, —NRaRb, and —C(O)NRcRd; or alternatively R2 and R3 together with the phosphorus atom to which they are attached form a 4- to 8-membered ring optionally substituted with one to five substituents independently selected from the group consisting of C1-C6 alkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, C3-C6 cycloalkyl, 3- to 10-membered heterocyclyl, halogen, cyano, nitro, —OR9, —SR9, —C(O)OR9, —C(O)R10, —NRaRb, —C(O)NRcRd, and oxo;
R4 at each occurrence is independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, or arylalkyl, each except hydrogen optionally substituted;
R5 and R6 are each independently selected from H, halogen, C1-C6 alkyl, and C1-C6 alkoxy; or R5 and R6 together form oxo (═O) or with the carbon atom to which they are attached form a 3- to 6-membered ring optionally substituted by one to five substituents independently selected from the group consisting of halogen, C1-C6 alkyl, and C1-C6 alkoxy;
R7 and R8 are independently selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, and 5- to 10-membered heterocyclyl; or alternatively, R7 and R8 together with the nitrogen atom to which they are attached, form a 4- to 6-membered ring, wherein said 4- to 6-membered ring optionally may contain one to five substituents independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, C6-C10 aryl, and —OR9;
B is aryl, heteroaryl, cycloalkyl, or heterocyclyl, each optionally substituted with one to five substituents independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C3-C6 cycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, CN, P(═O)(R9)2, P(═O)(OR9)2, —C(O)R10, —CO2R9, —OR9, —SR9, —NRaRb, —CONRaRb, —NR12C(O)R10, —NR12SO2R11, —NR12SO2NRaRb, —SO2R11, and —SO2NRaRb;
R9 at each occurrence is independently hydrogen, C1-C6 alkyl, or C6-C10 aryl;
R10 at each occurrence is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, C6-C10 aryl, or 5- to 10-membered heteroaryl, each except hydrogen optionally substituted;
R11 at each occurrence is independently selected from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl, C6-C10 aryl, and 5- to 10-membered heteroaryl, each optionally substituted;
R12 each occurrence is independently hydrogen, C1-C6 alkyl, or C3-C6 cycloalkyl;
wherein, unless specifically defined, cycloalkyl and heterocyclyl may optionally be fused onto an aromatic ring and may optionally be substituted with one to five substituents independently selected from the group consisting of halogen, cyano, nitro, —OR13, —SR13, C1-C6 alkyl, C6-C10 aryl, —NRaRb, and —C(O)OR14;
wherein, unless specifically defined, any said aryl and heteroaryl may optionally be substituted with one to five substituents independently selected from halogen, cyano, nitro, —OR13, —SR13, C1-C6 alkyl, C1-C6 haloalkyl, C6-C10 aryl, —C(O)OR14, —NRaRb, and —C(O)NcRd;
R13 at each occurrence is independently hydrogen, C1-C6 alkyl, or C1-C6 haloalkyl;
R14 at each occurrence is independently hydrogen or C1-C6 alkyl;
Ra and Rb are independently selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, and benzyl; and
Rc and Rd are independently hydrogen or C1-C6 alkyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein X is N, Y is C, and Z is N, having a structure of formula (II):
or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

### Claim 3 (depends on 1)

The compound of claim 1, wherein X is C, Y is N, and Z is CH, having a structure of formula (III):
or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

### Claim 4 (depends on 1)

The compound of claim 1, wherein X is C, Y is N, and Z is N, having a structure of formula (IV):
or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

### Claim 5 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein A is arylene or heteroarylene each optionally substituted by one to four substituents independent selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, and C1-C6 haloalkoxy.

### Claim 6 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein A is selected from the group consisting of:
each optionally substituted by one, two, or three substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, and C1-C4 haloalkoxy.

### Claim 7 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein L is absent or NR1, and Q is absent or C(RQ)2.

### Claim 8 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein L is absent, and Q is C(RQ)2.

### Claim 9 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein L is NR1, and Q is C(RQ)2.

### Claim 10 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein L is NR1, and Q is absent.

### Claim 11 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein L and Q are absent.

### Claim 12 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein A, L, and Q are all absent.

### Claim 13 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein B is heteroaryl or heterocyclyl, each optionally substituted with one to five substituents independently selected from the group consisting of halogen, CN, C1-C6 alkyl, C1-C6 haloalkyl, —C(O)R10, —CO2R9, —OR9, —NRaRb, —C(O)NRaRb, and —SO2NRaRb, wherein R9 is hydrogen or C1-C6 alkyl, R10 is C1-C4 alkyl, and Ra and Rb are each independently hydrogen or C1-C4 alkyl.

### Claim 14 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein B is selected from the group consisting of:
each optionally substituted by one, two, or three substituents independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, and C1-C6 haloalkoxy.

### Claim 15 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein W is C(R5R6), wherein R5 and R6 are each independently H, halogen, or C1-C4 alkyl.

### Claim 16 (depends on 1)

The compound of claim 1, wherein:
R2 and R3 are independently selected from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl, —OR4, —NR7R8, and —OCH2(C═O)OR9, wherein said alkyl or cycloalkyl is optionally substituted by one to four substituents independently selected from the group consisting of C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C6-C10 aryl, 5- to 10-membered heteroaryl, C3-C6 cycloalkyl, 3- to 10-membered heterocyclyl, halogen, cyano, nitro, —OR9, —SR9, —C(O)OR9, —C(O)R10, —NRaRb, and —C(O)NRcRd;
R4 is selected from the group consisting of hydrogen, C1-C6 alkyl, and benzyl;
R7 and R8 are independently selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, and C6-C10 aryl; or alternatively, R7 and R8 together with the nitrogen atom to which they are attached, form a 4- to 6-membered ring, wherein said 4- to 6-membered ring optionally may contain one to three substituents independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, C6-C10 aryl, and —OR9;
R9 at each occurrence is independently H, C1-C6 alkyl, or C6-C10 aryl;
R10 at each occurrence is independently selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, C6-C10 aryl, and 5- to 10-membered heteroaryl;
Ra and Rb are each independently hydrogen or C1-C6 alkyl; and
Rc and Rd are independently hydrogen or C1-C4 alkyl.

### Claim 17 (depends on 1)

The compound of claim 1, having a structure of formula (V), (VI), (VII), or (VIII):
or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein:
i is 1, 2, 3, or 4;
j is 1 or 2; and
RA at each occurrence is independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, C1-C6 acyl, cyano, nitro, and NRcRd;
L1 is a bond, O, S, NR1, or C(RL)2, wherein RL at each occurrence is independently hydrogen, halogen, or C1-C4 alkyl;
Q1 is a bond or C(RQ)2, wherein RQ at each occurrence is independently hydrogen, halogen, or C1-C4 alkyl;
R1 at each occurrence is independently H or C1-C4 alkyl;
R2 and R3 are each independently selected from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl, —NR7R8, OR4, and —OCH2(C═O)OR9, wherein the alkyl is optionally substituted by one to three substituents independently selected from the group consisting of C6-C10 aryl, 5- to 10-membered heteroaryl, C3-C6 cycloalkyl, 3- to 10-membered heterocyclyl, halogen, cyano, nitro, —OR9, —SR9, —C(O)OR9, —C(O)R10, —NRaRb, and —C(O)NRcRd
R4 at each occurrence is independently H, C1-C4 alkyl, or phenyl;
W1 is a bond or CR5R6, wherein R5 and R6 are each independently H, halogen, or C1-C4 alkyl, or R5 and R6 together with the carbon atom to which they are attached form a 3- to 6-membered ring optionally substituted;
R7 and R8 are independently selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, and 5- to 10-membered heterocyclyl; or alternatively, R7 and R8 together with the nitrogen atom to which they are attached, form a 4- to 6-membered ring, wherein said 4- to 6-membered ring optionally may contain one to three substituents independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, C6-C10 aryl, and —OR9;
“Het” is heteroaryl or heterocyclyl, each optionally substituted with one to four substituents independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C3-C6 cycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, and CN;
R9 at each occurrence is independently H or C1-6 alkyl;
R10 at each occurrence is independently H or C1-6 alkyl;
R13 at each occurrence is independently hydrogen, C1-C6 alkyl, or C1-C6 haloalkyl;
R14 at each occurrence is independently hydrogen or C1-C6 alkyl;
Ra and Rb are independently selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, and benzyl; and
Rc and Rd are independently hydrogen or C1-C6 alkyl.

### Claim 18 (depends on 917)

The compound of claim 917, or a pharmaceutically acceptable salt or solvate thereof, wherein L1 is absent or NR1, and Q1 is absent or C(RQ)2.

### Claim 19 (depends on 17)

The compound of claim 17, or a pharmaceutically acceptable salt or solvate thereof, wherein L1 is absent, and Q1 is C(RQ)2.

### Claim 20 (depends on 17)

The compound of claim 17, or a pharmaceutically acceptable salt or solvate thereof, wherein L1 is NR1, and Q1 is C(RQ)2.

### Claim 21 (depends on 917)

The compound of claim 917, or a pharmaceutically acceptable salt or solvate thereof, wherein L1 is NR1, and Q1 is absent.

### Claim 22 (depends on 17)

The compound of claim 17, or a pharmaceutically acceptable salt or solvate thereof, wherein L1 and Q1 are both absent.

### Claim 23 (depends on 17)

The compound of claim 17, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the Het is selected from the group consisting of:
each optionally substituted by one, two, or three substituents independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, and C1-C6 haloalkoxy.

### Claim 24 (depends on 17)

The compound of claim 17, wherein R2 and R3 are independently selected from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl, —OR4, —NR7R8, and —OCH2(C═O)OR9, wherein said alkyl or cycloalkyl is optionally substituted by one to four substituents independently selected from the group consisting of C1-C4 alkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, and C3-C6 cycloalkyl; wherein R4 is hydrogen or C1-C6 alkyl, R7 and R8 are independently hydrogen or C1-C4 alkyl, and R9 is C1-C4 alkyl.

### Claim 25 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate or prodrug thereof, selected from the Compound List 1.

### Claim 26 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate or prodrug thereof, selected from the group consisting of:

### Claim 27 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable carrier.

### Claim 28 (depends on 1)

A method of treating a disease or disorder in a subject, comprising administering to the subject a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, solvate or prodrug thereof.

### Claim 29 (depends on 28)

The method of claim 28, wherein the disease or disorder is associated with tyrosine kinase c-MET activity.

### Claim 30 (depends on 28)

The method of claim 28, wherein the disease or disorder is selected from the group consisting of gastric cancer, lung cancer (e.g., non-small cell lung cancer), colon cancer, breast cancer, pancreatic cancer, esophageal cancer, colorectal cancers, ovarian cancers, glioblastomas, hepatocellular cancer, melanoma, sarcoma, fibrosarcoma, osteoma, neuroblastoma, teratocarcinoma, retinoblastoma, rhabdomyosarcoma, hematopoietic malignancy, malignant ascites, atherosclerosis, and fibrosis of the lung.

### Claim 31 (depends on 1)

Use of a compound according to claim 1, or a pharmaceutically acceptable salt, solvate or prodrug thereof, in the manufacture of a medicament for treatment of a disease or disorder associated with tyrosine kinase c-MET activity.
